Alzheimer's disease therapeutics increasingly target amyloid-β (Aβ) plaques using monoclonal antibodies, exemplified by lecanemab and donanemab, which show modest cognitive benefits linked to amyloid reduction. However, their impact on brain function remain... ...

请注册登录后继续浏览